OBJECTIVE: This study compares patient characteristics and treatment response between inpatients treated with clozapine in a research setting as compared to those initiated on clozapine during routine inpatient treatment. METHODS: Subjects on clozapine, in clinical trials, were compared with clozapine inpatients receiving routine clinical care. RESULTS: At baseline, patients in routine clinical practice had more negative symptoms (P < 0.001), activation (P < 0.001) and greater total Brief Psychiatric Rating Scale (BPRS) scores (P = 0.022) than those in the research setting. Routine clinical practice subjects had larger decreases in BPRS total scores (P = 0.042) and positive item scores (P = 0.0005) compared to research subjects. Response to clozapine was observed in 15/85 (18%) research subjects as compared to 60/223 (27%) patients in routine care (P = 0.09). CONCLUSIONS: Patients treated in routine clinical practice have more severe baseline symptoms, but experience significantly greater improvements in psychiatric symptoms.
OBJECTIVE: This study compares patient characteristics and treatment response between inpatients treated with clozapine in a research setting as compared to those initiated on clozapine during routine inpatient treatment. METHODS: Subjects on clozapine, in clinical trials, were compared with clozapine inpatients receiving routine clinical care. RESULTS: At baseline, patients in routine clinical practice had more negative symptoms (P < 0.001), activation (P < 0.001) and greater total Brief Psychiatric Rating Scale (BPRS) scores (P = 0.022) than those in the research setting. Routine clinical practice subjects had larger decreases in BPRS total scores (P = 0.042) and positive item scores (P = 0.0005) compared to research subjects. Response to clozapine was observed in 15/85 (18%) research subjects as compared to 60/223 (27%) patients in routine care (P = 0.09). CONCLUSIONS:Patients treated in routine clinical practice have more severe baseline symptoms, but experience significantly greater improvements in psychiatric symptoms.
Authors: Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl Journal: Am J Psychiatry Date: 2004-02 Impact factor: 18.112
Authors: Daniel S Umbricht; William C Wirshing; Donna A Wirshing; Marjorie McMeniman; Nina R Schooler; Stephen R Marder; John M Kane Journal: J Clin Psychiatry Date: 2002-05 Impact factor: 4.384
Authors: Anthony F Lehman; Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon; Richard Goldberg; Lisa D Green-Paden; Wendy N Tenhula; Daniela Boerescu; Cenk Tek; Neil Sandson; Donald M Steinwachs Journal: Schizophr Bull Date: 2004 Impact factor: 9.306
Authors: A Breier; R W Buchanan; B Kirkpatrick; O R Davis; D Irish; A Summerfelt; W T Carpenter Journal: Am J Psychiatry Date: 1994-01 Impact factor: 18.112